44 related articles for article (PubMed ID: 21383727)
1. Eyes on New Product Development.
Novack GD
J Ocul Pharmacol Ther; 2020 Apr; 36(3):135-136. PubMed ID: 32074465
[No Abstract] [Full Text] [Related]
2. How current assay approval policies are leading to unintended imprecision medicine.
Salgado R; Bellizzi AM; Rimm D; Bartlett JMS; Nielsen T; Holger M; Laenkholm AV; Quinn C; Cserni G; Cunha IW; Alvarado-Cabrero I; Cree I
Lancet Oncol; 2020 Nov; 21(11):1399-1401. PubMed ID: 33098760
[No Abstract] [Full Text] [Related]
3. Califf takes the helm at the US FDA, again.
Jaffe S
Lancet; 2022 Mar; 399(10330):1105-1106. PubMed ID: 35305729
[No Abstract] [Full Text] [Related]
4. It takes two to tango: The dance of cell fate specification.
Song Y
Dev Biol; 2022 Oct; 490():125. PubMed ID: 35940227
[No Abstract] [Full Text] [Related]
5. Dual Pathway Inhibition in Stable Cardiovascular Disease: It Takes Two to Tango!
Romeo FJ
J Cardiovasc Pharmacol; 2024 May; ():. PubMed ID: 38922582
[No Abstract] [Full Text] [Related]
6. The immune system, cancer, and pathogens: It takes three to tango!
Hajjar J
J Immunother Precis Oncol; 2021 May; 4(2):33-34. PubMed ID: 35663530
[No Abstract] [Full Text] [Related]
7. It takes one to tango: Hybrid leader.
Tay YX; Wei YM
J Med Imaging Radiat Sci; 2022 Dec; 53(4S):S65-S67. PubMed ID: 36151022
[No Abstract] [Full Text] [Related]
8. Induction of cell cycle arrest and apoptosis in caspase-3 deficient MCF-7 cells by Dillenia suffruticosa root extract via multiple signalling pathways.
Foo JB; Yazan LS; Tor YS; Armania N; Ismail N; Imam MU; Yeap SK; Cheah YK; Abdullah R; Ismail M
BMC Complement Altern Med; 2014 Jun; 14():197. PubMed ID: 24947113
[TBL] [Abstract][Full Text] [Related]
9. Cancer nanotherapeutics in clinical trials.
Lytton-Jean AK; Kauffman KJ; Kaczmarek JC; Langer R
Cancer Treat Res; 2015; 166():293-322. PubMed ID: 25895874
[TBL] [Abstract][Full Text] [Related]
10. When it takes two to tango, FDA suggests a new regulatory dance.
Dolgin E
Nat Med; 2011 Mar; 17(3):270. PubMed ID: 21383727
[No Abstract] [Full Text] [Related]
11. New clinical trials policy at FDA.
Vastag B
Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
[No Abstract] [Full Text] [Related]
12. FDA and drug approval.
Faich GA
J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):24S. PubMed ID: 8770838
[No Abstract] [Full Text] [Related]
13. The role of the fDA in cancer clinical trials.
Hirschfeld S
Cancer Treat Res; 2007; 132():51-109. PubMed ID: 17305017
[No Abstract] [Full Text] [Related]
14. Regulatory issues with multiplicity in drug approval: Principles and controversies in a changing landscape.
Benda N; Brandt A
J Biopharm Stat; 2018; 28(1):3-9. PubMed ID: 29065277
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
